当前位置：
首页
>
产品中心 >
clinical_research >
absoluteantibody/Ab00188-35.0 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-35.0/ 200 µg
![absoluteantibody/Ab00188-35.0 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-35.0/ 200 µg](https://www.ebiomall.cn/images/absoluteantibody/IMG00155Ab00188-23.0FCfull.png)
absoluteantibody/Ab00188-35.0 Anti-IL-2R alpha (CD25) [Basiliximab]/Ab00188-35.0/ 200 µg
商品编号：
Ab00188-35.0
品牌：
absoluteantibody
市场价：
¥6384.00
美元价：
3830.40
产品分类：
临床研究
公司分类：
clinical_research
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Description:RecombinantmonoclonalantibodytoIL-2Ralpha(CD25).ManufacturedusingAbAb’sRecombinantPlatformwithvariableregions(i.e.specificity)fromthetherapeuticantibodyBasiliximab.
CloneNumber:Basiliximab
UniProtAccessionNumberofTargetProtein:P01589
PublishedApplication(s):FC;Block;IF;IHC;WB
PublishedSpeciesReactivity:Human;RhesusMonkey;CynomolgusMonkey
Immunogen:BasiliximabwaspreparedbyimmunizingBALB/cmicewithCTC16cells.
Specificity:BasiliximabrecognisesthehumanIL-2Randbindstotheepitope(116)ERIYHFV(122)withintheextracellulardomainoftheCD25subunit–bindingisabolishedwhen2ormoreresidueswithintheepitopearemutated.ThisepitopeoverlapswiththeinteractionsiteofCD25andIL-2.CD25isfoundinthehigh-affinityIL-2R(αβγc)–TcellsonlyexpressCD25uponactivation.IL-2bindingtoIL-2RonTcellsmodulatesproliferationanddifferentiation.
ApplicationNotes:Basiliximabisderivedfromthemurineanti-Tacantibody.Fortheclinicallyusedformat,thevariableregionsfromthisantibodyweregraftedontothesequenceofthehumanIgG1κconstantregions.BasiliximabbindingtoCD25competitivelyblockstheinteractionofIL-2RwithitsligandIL-2onthesurfaceofTcells.BlockingthisinteractionpreventsTcellreplicationandTcell-mediatedBcellactivation.Basiliximabbindingsuppressestheimmunesysteminhibitsthepathwayactivatingthecellularimmuneresponsetoallograftrejection.IL-2signallingsuppressioncanadditionallypreventacutegraft-versus-hostdisease,autoimmunedisordersandmalignanciessuchasTcellleukemias(Binderetal,2007).BasiliximabhasalsobeenusedinFC,IF,IHCandWBstudies,whichenablesthedetectionofCD25.
AntibodyFirstPublishedin:
Kovariketal.Dispositionofbasiliximab,aninterleukin-2receptormonoclonalantibody,inrecipientsofmismatchedcadaverrenalallografts.Transplantation.1997Dec27;64(12):1701-5.PMID:9422405Noteonpublication:Describesthecharacterizationofthepharmacokineticsofthetherapeuticantibody.
Concentration:Seeviallabel.
Importantnote–Thisproductisforresearchuseonly.Itisnotintendedforuseintherapeuticordiagnosticproceduresforhumansoranimals.ThischimericcynomolgusmonkeyantibodywasmadeusingthevariabledomainsequencesoftheoriginalHumanIgG1format,forimprovedcompatibilitywithexistingreagents,assaysandtechniques.
SpeciesandIsotype:CynomolgusmonkeyIgG1,kappaCloneNumber:Basiliximab
UniProtAccessionNumberofTargetProtein:P01589
PublishedApplication(s):FC;Block;IF;IHC;WB
PublishedSpeciesReactivity:Human;RhesusMonkey;CynomolgusMonkey
Immunogen:BasiliximabwaspreparedbyimmunizingBALB/cmicewithCTC16cells.
Specificity:BasiliximabrecognisesthehumanIL-2Randbindstotheepitope(116)ERIYHFV(122)withintheextracellulardomainoftheCD25subunit–bindingisabolishedwhen2ormoreresidueswithintheepitopearemutated.ThisepitopeoverlapswiththeinteractionsiteofCD25andIL-2.CD25isfoundinthehigh-affinityIL-2R(αβγc)–TcellsonlyexpressCD25uponactivation.IL-2bindingtoIL-2RonTcellsmodulatesproliferationanddifferentiation.
ApplicationNotes:Basiliximabisderivedfromthemurineanti-Tacantibody.Fortheclinicallyusedformat,thevariableregionsfromthisantibodyweregraftedontothesequenceofthehumanIgG1κconstantregions.BasiliximabbindingtoCD25competitivelyblockstheinteractionofIL-2RwithitsligandIL-2onthesurfaceofTcells.BlockingthisinteractionpreventsTcellreplicationandTcell-mediatedBcellactivation.Basiliximabbindingsuppressestheimmunesysteminhibitsthepathwayactivatingthecellularimmuneresponsetoallograftrejection.IL-2signallingsuppressioncanadditionallypreventacutegraft-versus-hostdisease,autoimmunedisordersandmalignanciessuchasTcellleukemias(Binderetal,2007).BasiliximabhasalsobeenusedinFC,IF,IHCandWBstudies,whichenablesthedetectionofCD25.
AntibodyFirstPublishedin:
Kovariketal.Dispositionofbasiliximab,aninterleukin-2receptormonoclonalantibody,inrecipientsofmismatchedcadaverrenalallografts.Transplantation.1997Dec27;64(12):1701-5.PMID:9422405Noteonpublication:Describesthecharacterizationofthepharmacokineticsofthetherapeuticantibody.
ProductForm
Purification:ProteinAaffinitypurifiedSuppliedin:PBSonly.
StorageRecommendation:Storeat4°Cforupto3months.Forlongertermstoragealiquotintosmallvolumesandstoreat-20°CConcentration:Seeviallabel.
品牌介绍
Absolute antibody本公司服务于抗体测序、制造和工程服务提供给所有抗体使用者和不断增长的抗体。Absolute Antibody Ltd was founded in Oxford, UK, in August 2012, with the vision that all antibody users should be able to use recombinant antibodies, which are absolutely defined by their amino acid sequence. This view gained support in 2015 with a Comment in Nature magazine by Bradbury and Pluckthun (+110 co-signatories) – “Reproducibility: Standardize antibodies used in research“. Rather than creating entirely new antibodies (or antibody-like molecules), we are building a catalog by taking existing antibodies (often from hybridomas) then manufacturing them in a superior way and improving their usefulness by engineering.品牌货号名称规格absoluteantibody21 E11Anti-Api m 21 kitabsoluteantibodyBAB2Anti-Bet v 1 1 kitabsoluteantibodyBAB3Anti-Bet v 11 kitabsoluteantibodyBAB4Anti-Bet v 11 kitabsoluteantibodyBAB5Anti-Bet v 1 1 kitabsoluteantibodyBV16Anti-Bet v 1 1 kitabsoluteantibodyM0418Anti-Bet v 11 kitabsoluteantibody4C3Anti-Bla g 2 1 kitabsoluteantibody7C11Anti-Bla g 21 kitabsoluteantibodyD1Anti-Bos d 5 1 kitabsoluteantibody6A8Anti-Der f 11 kitabsoluteantibody10B9Anti-Der p 11 kitabsoluteantibody5H8Anti-Der p 11 kitabsoluteantibody4C1Anti-Neurotoxin AahII1 kitabsoluteantibodyH10Anti-Der p 21 kit
品牌分类
关注表位标记
Primary Antibodies
Recombinant Antibodies from Human Patients
Anti-Allergen Antibodies
多标签控制蛋白
Recombinant Isotype Controls
抗过敏原抗体
重组F4/80克隆CI:A3-1
体内研究用重组抗体
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
